Gambaran Umum
Aclaris Therapeutics, Inc., based in the United States, operates in the biopharmaceutical industry where it focuses on developing novel drug candidates and technologies to address unmet needs in medical and aesthetic dermatology as well as immunodermatology. The company is particularly acclaimed for its pipeline projects aimed at treating skin disorders like alopecia areata, vitiligo, and common warts. Among their various stages of research and development, Aclaris emphasizes innovation in small molecule therapeutics, seeking to harness scientific advancements to deliver tangible solutions for complex skin conditions. Their strategic approach involves identifying and rapidly advancing a portfolio of proprietary compounds with potential significant commercial prospects in dermatologically related conditions.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Aclaris Therapeutics, Inc. per 2025 Jun 30 adalah 16.79 MM.
- Nilai operating income untuk Aclaris Therapeutics, Inc. per 2025 Jun 30 adalah -58.43 MM.
- Nilai net income untuk Aclaris Therapeutics, Inc. per 2025 Jun 30 adalah -134.65 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 16.79 | -58.43 | -134.65 |
2025-03-31 | 17.78 | -54.18 | -130.21 |
2024-12-31 | 18.72 | -52.53 | -132.06 |
2024-09-30 | 27.08 | -62.17 | -37.00 |
2024-06-30 | 32.02 | -79.26 | -58.68 |
2024-03-31 | 31.12 | -99.92 | -77.26 |
2023-12-31 | 31.25 | -114.51 | -88.48 |
2023-09-30 | 21.43 | -115.89 | -114.62 |
2023-06-30 | 31.17 | -104.69 | -105.32 |
2023-03-31 | 30.83 | -95.77 | -96.28 |
2022-12-31 | 29.75 | -85.15 | -86.91 |
2022-09-30 | 23.50 | -83.87 | -82.08 |
2022-06-30 | 6.14 | -84.59 | -83.27 |
2022-03-31 | 6.44 | -73.40 | -80.90 |
2021-12-31 | 6.76 | -65.38 | -90.86 |
2021-09-30 | 6.84 | -58.25 | -81.23 |
2021-06-30 | 6.63 | -48.70 | -70.75 |
2021-03-31 | 6.85 | -46.87 | -64.18 |
2020-12-31 | 6.48 | -48.52 | -51.02 |
2020-09-30 | 6.00 | -52.51 | -56.44 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Aclaris Therapeutics, Inc. pada 2025 Jun 30 adalah -1.31.
- laba per saham yang terdilusi untuk Aclaris Therapeutics, Inc. pada 2025 Jun 30 adalah -1.31.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -1.31 | -1.31 |
2025-03-31 | -1.44 | -1.45 |
2024-12-31 | -1.71 | -1.71 |
2024-09-30 | -0.52 | -0.52 |
2024-06-30 | -0.83 | -0.83 |
2024-03-31 | -1.09 | -1.09 |
2023-12-31 | -1.27 | -1.27 |
2023-09-30 | -1.67 | -1.66 |
2023-06-30 | -1.55 | -1.55 |
2023-03-31 | -1.45 | -1.44 |
2022-12-31 | -1.33 | -1.33 |
2022-09-30 | -1.29 | -1.29 |
2022-06-30 | -1.33 | -1.33 |
2022-03-31 | -1.36 | -1.36 |
2021-12-31 | -1.60 | -1.60 |
2021-09-30 | -1.55 | -1.55 |
2021-06-30 | -1.48 | -1.48 |
2021-03-31 | -1.44 | -1.44 |
2020-12-31 | -1.20 | |
2020-09-30 | -1.34 | -1.34 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Aclaris Therapeutics, Inc. per 2025 Jun 30 adalah -9.99 MM.
- Nilai cash from investing activities untuk Aclaris Therapeutics, Inc. per 2025 Jun 30 adalah -61.76 MM.
- Nilai kas dari aktivitas pendanaan untuk Aclaris Therapeutics, Inc. per 2025 Jun 30 adalah 74.32 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -9.99 | -61.76 | 74.32 |
2025-03-31 | -12.32 | -67.48 | 74.32 |
2024-12-31 | -20.07 | -69.77 | 74.54 |
2024-09-30 | -17.90 | 26.50 | 0.01 |
2024-06-30 | -64.45 | 56.24 | -0.10 |
2024-03-31 | -72.79 | 37.26 | 26.65 |
2023-12-31 | -78.33 | 46.22 | 26.71 |
2023-09-30 | -90.68 | 41.37 | 26.69 |
2023-06-30 | -73.94 | 10.05 | 26.77 |
2023-03-31 | -72.95 | 8.49 | 72.84 |
2022-12-31 | -67.57 | 12.63 | 72.87 |
2022-09-30 | -65.53 | 0.75 | 72.83 |
2022-06-30 | -68.32 | -38.14 | 61.27 |
2022-03-31 | -60.87 | -62.39 | 124.33 |
2021-12-31 | -52.13 | -167.63 | 225.05 |
2021-09-30 | -43.92 | -160.76 | 232.88 |
2021-06-30 | -45.46 | -117.85 | 244.17 |
2021-03-31 | -44.06 | -82.87 | 108.20 |
2020-12-31 | -38.63 | 6.39 | 18.37 |
2020-09-30 | -50.17 | 65.13 | -19.47 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/libro untuk Aclaris Therapeutics, Inc. pada 2025 Jun 30 adalah 1.07.
- p/tbv untuk Aclaris Therapeutics, Inc. pada 2025 Jun 30 adalah 1.07.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | 1.07 | 1.07 | |
2025-03-31 | 1.10 | 1.10 | |
2024-12-31 | 2.04 | 2.04 | |
2024-09-30 | -1.42 | 0.62 | 0.62 |
2024-06-30 | -1.02 | 0.56 | 0.56 |
2024-03-31 | -1.01 | 0.57 | 0.57 |
2023-12-31 | -0.65 | 0.48 | 0.50 |
2023-09-30 | -4.62 | 2.71 | 2.81 |
2023-06-30 | -7.52 | 4.10 | 4.27 |
2023-03-31 | -6.20 | 2.73 | |
2022-12-31 | -12.79 | 4.77 | 4.93 |
2022-09-30 | 4.45 | 4.59 | |
2022-06-30 | -11.49 | 5.16 | 5.37 |
2022-03-31 | -11.63 | 5.35 | 5.55 |
2021-12-31 | -10.96 | 4.11 | 4.25 |
2021-09-30 | -15.51 | 4.69 | 4.84 |
2021-06-30 | |||
2021-03-31 | -12.25 | 7.00 | 7.48 |
2020-12-31 | -13.35 | 18.09 | 22.31 |
2020-09-30 | -11.48 | 15.90 | 19.28 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Aclaris Therapeutics, Inc. pada 2025 Jun 30 adalah -1.05.
- EBIT (3 tahun) / EV untuk Aclaris Therapeutics, Inc. pada 2025 Jun 30 adalah -0.79.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -1.05 | -0.79 |
2025-03-31 | -0.90 | -0.69 |
2024-12-31 | -0.17 | -0.33 |
2024-09-30 | -0.97 | -1.41 |
2024-06-30 | -1.79 | -1.96 |
2024-03-31 | -1.80 | -1.80 |
2023-12-31 | -3.24 | -2.63 |
2023-09-30 | -0.23 | -0.19 |
2023-06-30 | -0.14 | -0.12 |
2023-03-31 | -0.18 | -0.16 |
2022-12-31 | -0.08 | -0.07 |
2022-09-30 | -0.08 | -0.08 |
2022-06-30 | -0.09 | -0.08 |
2022-03-31 | -0.09 | -0.08 |
2021-12-31 | -0.10 | -0.10 |
2021-09-30 | -0.07 | -0.10 |
2021-06-30 | ||
2021-03-31 | -0.09 | -0.13 |
2020-12-31 | -0.08 | -0.15 |
2020-09-30 | -0.09 | -0.18 |
Efektivitas Manajemen
- roa untuk Aclaris Therapeutics, Inc. pada 2025 Jun 30 adalah -0.81.
- roe untuk Aclaris Therapeutics, Inc. pada 2025 Jun 30 adalah -0.97.
- roic untuk Aclaris Therapeutics, Inc. pada 2025 Jun 30 adalah -0.89.
- croic untuk Aclaris Therapeutics, Inc. pada 2025 Jun 30 adalah -0.04.
- ocroic untuk Aclaris Therapeutics, Inc. pada 2025 Jun 30 adalah -0.08.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.81 | -0.97 | -0.89 | -0.04 | -0.08 |
2025-03-31 | -0.76 | -0.93 | -0.84 | -0.10 | -0.13 |
2024-12-31 | -0.19 | -0.24 | -0.28 | 0.06 | -0.13 |
2024-09-30 | -0.27 | -0.38 | -0.43 | -0.06 | -0.47 |
2024-06-30 | -0.34 | -0.44 | -0.53 | -0.06 | -0.50 |
2024-03-31 | -0.35 | -0.45 | -0.55 | -0.03 | -0.49 |
2023-12-31 | -0.43 | -0.52 | -0.72 | -0.14 | -0.57 |
2023-09-30 | -0.38 | -0.45 | -0.58 | -0.20 | -0.41 |
2023-06-30 | -0.35 | -0.41 | -0.58 | -0.20 | -0.41 |
2023-03-31 | -0.38 | -0.48 | -0.54 | 0.05 | -0.41 |
2022-12-31 | -0.31 | -0.38 | -0.37 | 0.04 | -0.29 |
2022-09-30 | -0.32 | -0.38 | -0.37 | 0.04 | -0.29 |
2022-06-30 | -0.28 | -0.35 | -0.35 | -0.19 | -0.29 |
2022-03-31 | -0.56 | -0.81 | -0.44 | 0.01 | -0.33 |
2021-12-31 | -1.15 | -2.16 | -0.43 | 0.03 | -0.19 |
2021-09-30 | -1.13 | -1.74 | -0.35 | 0.12 | -0.18 |
2021-06-30 | -0.83 | -1.43 | -0.29 | 0.33 | -0.18 |
2021-03-31 | -0.66 | -1.10 | -0.51 | -0.15 | -0.35 |
2020-12-31 | -0.52 | -0.73 | -0.98 | -0.27 | -0.75 |
2020-09-30 | -0.35 | -0.66 | -1.03 | -0.08 | -0.91 |
Gross Margins
- marjin kotor untuk Aclaris Therapeutics, Inc. pada 2025 Jun 30 adalah -1.84.
- marjin bersih untuk Aclaris Therapeutics, Inc. pada 2025 Jun 30 adalah -7.32.
- marjin operasi untuk Aclaris Therapeutics, Inc. pada 2025 Jun 30 adalah -3.05.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | -1.84 | -7.32 | -3.05 |
2025-03-31 | -1.62 | -7.05 | -2.81 |
2024-12-31 | -2.84 | -1.37 | -2.30 |
2024-09-30 | -1.73 | -1.83 | -2.57 |
2024-06-30 | -2.33 | -2.48 | -3.31 |
2024-03-31 | -2.73 | -2.83 | -3.76 |
2023-12-31 | -3.57 | -5.35 | -5.41 |
2023-09-30 | -2.39 | -3.38 | -3.36 |
2023-06-30 | -2.02 | -3.38 | -3.36 |
2023-03-31 | -2.02 | -3.12 | -3.11 |
2022-12-31 | -2.51 | -3.49 | -3.57 |
2022-09-30 | -9.69 | -3.49 | -3.57 |
2022-06-30 | -7.54 | -13.56 | -13.77 |
2022-03-31 | -6.18 | -12.57 | -11.40 |
2021-12-31 | -4.00 | -13.44 | -9.67 |
2021-09-30 | -4.41 | -11.88 | -8.52 |
2021-06-30 | -4.41 | -10.67 | -7.34 |
2021-03-31 | -4.04 | -9.37 | -6.84 |
2020-12-31 | -4.32 | -7.87 | -7.49 |
2020-09-30 | -5.24 | -9.41 | -8.86 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1557746 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |